Testosterone transdermal - ANI Pharmaceuticals/Antares

Drug Profile

Testosterone transdermal - ANI Pharmaceuticals/Antares

Alternative Names: Bio-T-Gel; LibiGel; Male testosterone gel - ANI Pharmaceuticals/Teva Pharmaceuticals USA; Testosterone ATD™ Gel; Testosterone topical gel - ANI Pharmaceuticals/Antares; Testosterone transdermal - Antares/BioSante

Latest Information Update: 16 May 2015

Price : $50

At a glance

  • Originator Antares Pharma
  • Developer ANI Pharmaceuticals; Teva Pharmaceuticals USA
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Hypogonadism
  • No development reported Cognition disorders; Female sexual dysfunction

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 13 May 2015 Testosterone transdermal is no longer licensed to Teva in USA
  • 05 Apr 2015 Testosterone transdermal is still registered for Hypogonadism in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top